UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
 WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):   July 19, 2007
Acorda Therapeutics, Inc.
 (Exact name of registrant as specified in its charter)

 Delaware	 	000-50513	 	13-3831168	
(State or other jurisdiction	 	(Commission	 	(I.R.S. Employer	
Of incorporation)	 	File Number)	 	Identification No.)	

 15 Skyline Drive, Hawthorne, NY	 	10532	
(Address of principal executive offices)	 	(Zip Code)	
 
Registrant’s telephone number, including area code:   (914) 347-4300
Not Applicable
 Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 
Item 1.02 Termination of a Material Definitive Agreement.
On July 19, 2007, Mary Fisher, the Chief Operating Officer of Acorda Therapeutics, Inc. (the “Registrant” or the “Company”) tendered her resignation, effective immediately, as an officer and employee of  the Company, to pursue other interests.  As a result, except as specifically provided therein, the employment agreement, dated December 19, 2005, as amended, between the Company and Ms. Fisher, will no longer remain in effect.
 
 Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Principal Officers.
The Registrant announced in a press release issued July 20, 2007 that Mary Fisher resigned as the Chief Operating Officer of the Company on July 19, 2007, effective immediately, to pursue other interests. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference into this Item.  The information set forth under Item 1.02 above is incorporated into this Item 5.02.
 
Item 9.01 Financial Statements and Exhibits
99.1 Press Release dated July 20, 2007
2

 
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Acorda Therapeutics, Inc.	

July 20, 2007	By:	/s/ David Lawrence	
 	 	Name: David Lawrence	
 	 	Title: Chief Financial Officer	
 
3

Exhibit Index

 Exhibit No.	 	Description	
 	 	 	
99.1	 	Press Release dated July 20, 2007	

 
 
Exhibit 99.1
CONTACTS:
Erica Wishner
Acorda Therapeutics
(914) 347-4300 ext. 162
ewishner@acorda.com
 
FOR IMMEDIATE RELEASE

Acorda Therapeutics Announces Resignation of Mary Fisher
HAWTHORNE, New York, July 20, 2007- Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced today the resignation, effective immediately, of  Mary Fisher, Chief Operating Officer, to pursue other interests.
“All of us at Acorda thank Mary for her many contributions to the Company during the past seven years,” said Ron Cohen, M.D., President and CEO. “She is a person of great talent and accomplishment, and we wish her the best in her future endeavors.”
“I’m very grateful to have been part of Acorda Therapeutics,” said Mary Fisher. “It is a remarkable organization, and I’m sure they will have great success in the future.”
About Acorda Therapeutics
Acorda Therapeutics is a biotechnology company developing therapies for SCI, MS and related nervous system disorders.  The Company’s marketed products include Zanaflex Capsules™ (tizanidine hydrochloride), a short-acting drug for the management of spasticity.  Acorda’s lead clinical product, Fampridine-SR, is in a Phase 3 clinical trial to evaluate its safety and efficacy in improving walking ability in people with MS. The Company’s pipeline includes a number of products in development for the treatment, regeneration and repair of the spinal cord and brain.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  All statements, other than statements of historical facts, regarding management’s expectations, beliefs, goals, plans or prospects should be considered forward-looking.  These statements are subject to risks and uncertainties that could cause actual results to differ materially, including Acorda Therapeutics’ ability to successfully market and sell Zanaflex Capsules, the risk of unfavorable results from future studies of Fampridine-SR, delays in obtaining or failure to obtain FDA approval of Fampridine-SR, competition, the ability to obtain additional financing to support Acorda Therapeutics’ operations, unfavorable results from its preclinical programs, and failure to protect its intellectual property or to defend against the intellectual property claims of others.  These and other risks are described in greater detail in Acorda Therapeutics’ filings with the Securities and Exchange Commission.  Acorda Therapeutics may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. Acorda Therapeutics disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.